TuHURA Biosciences, Inc. HURA Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by TuHURA Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: TuHURA Biosciences, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about TuHURA Biosciences, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TuHURA Biosciences, Inc.'s cash & equivalents?
- TuHURA Biosciences, Inc. (HURA) reported cash & equivalents of $6.3M in Q1 2026.
- How has TuHURA Biosciences, Inc.'s cash & equivalents changed year-over-year?
- TuHURA Biosciences, Inc.'s cash & equivalents increased by 1.3% year-over-year, from $6.22M to $6.3M.
- What is the long-term trend for TuHURA Biosciences, Inc.'s cash & equivalents?
- Over 3 years (2022 to 2025), TuHURA Biosciences, Inc.'s cash & equivalents has grown at a -9.4% compound annual growth rate (CAGR), from $4.87M to $3.62M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.